AbbVie Just Bet $10.9 Billion on a Company That Didn't Exist Three Years Ago
AbbVie is paying $10.9 billion for a company that was founded in 2022 and has zero approved drugs. The bet: a next-gen eczema and asthma antibody that could challenge Dupixent with shots every three to six months instead of every two weeks.
From Zero to $10.9 Billion in Record Time
In February 2022, Apogee Therapeutics didn't exist. It was an idea scribbled on a whiteboard at Paragon Therapeutics, a biologics discovery shop. By July 2023, it had IPO'd on Nasdaq at $17 a share. And now, in July 2026, AbbVie is buying the whole thing for $135.11 per share in cash.
That's roughly a 400% premium to Apogee's closing price on June 18. It values the company at roughly $10.9 billion. And it marks AbbVie's largest acquisition in more than five years.
The question isn't whether AbbVie overpaid. The question is whether it had a choice.
The Humira Hangover Is Real
To understand why AbbVie would write a nearly $11 billion check for a company with zero approved drugs, you have to understand the hole it's trying to fill.
Humira was once the best-selling drug on the planet. At its peak, it generated more annual revenue than some countries' GDP. Then U.S. biosimilars arrived in 2023, and the slow bleed began. Revenue dropped. Margins tightened. AbbVie's entire corporate strategy had to pivot around a single, uncomfortable reality: the golden goose wasn't laying golden eggs anymore.
AbbVie's answer has been Skyrizi (an IL-23 inhibitor for psoriasis and IBD) and Rinvoq (a JAK1 inhibitor for rheumatoid arthritis and more). Both are growing fast. AbbVie expects them to combine for over $31 billion in sales by 2027, which would more than replace Humira's lost revenue. The company says total sales should return to robust growth starting in 2025, with a high-single-digit compound annual growth rate through 2029.
So if Skyrizi and Rinvoq are crushing it, why go shopping?
Because pharma is a treadmill. Today's blockbusters eventually face their own patent cliffs. AbbVie needs the next next thing. And Apogee might be it.
What Apogee Actually Has
Apogee's crown jewel is zumilokibart (also called APG777), a lab-engineered antibody that blocks IL-13, a protein that drives inflammation in conditions like atopic dermatitis (severe eczema) and asthma.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Now, blocking IL-13 isn't a new idea. Sanofi and Regeneron's Dupixent does something similar by targeting the IL-4 receptor alpha, which sits upstream and blocks both IL-4 and IL-13 signaling. Dupixent is a monster: it dominates atopic dermatitis, asthma, and several other conditions. Mordor Intelligence estimates it controlled roughly 55-60% of biologic revenue in atopic dermatitis in 2025.
So why would anyone try to compete with Dupixent? Two words: dosing convenience.
Dupixent requires an injection every two weeks. Zumilokibart is designed with a half-life extension that could allow dosing every three to six months. Think about that difference from a patient's perspective. Instead of 26 shots a year, you might need two to four. That's not an incremental improvement; it's a lifestyle change.
The Data That Caught AbbVie's Eye
Apogee ran a Phase 2 trial called APEX in adults with moderate-to-severe atopic dermatitis. The 16-week results were striking.
The response rates told a compelling story. About 65.9% of zumilokibart patients hit the EASI-75 benchmark (meaning their eczema improved by at least 75%), versus 23.4% on placebo. Those are the kind of numbers that make dermatologists sit up straight.
But the real kicker came from the 52-week maintenance data. Responses didn't just hold; they deepened over time, even when patients were dosed only every three or six months. In a chronic disease where patients often lose enthusiasm for frequent injections, that durability could be a massive competitive advantage.
Apogee has a dose-optimization study (Part B of the trial) with results expected around now, and Phase 3 trials are slated to begin in the second half of 2026. That timeline lines up perfectly with AbbVie's commercial machine kicking in to run late-stage development and eventual launch.
The Bigger Play: It's Not Just One Drug
AbbVie isn't buying Apogee for a single asset. It's buying a platform.
Beyond zumilokibart in atopic dermatitis, Apogee has laid out plans for the same drug in asthma and eosinophilic esophagitis (a chronic inflammatory condition of the esophagus). Those trials haven't produced data yet, but the indications are massive. Asthma biologics alone represent a multi-billion-dollar market dominated by Dupixent, AstraZeneca's tezepelumab (the only approved anti-TSLP biologic), and GSK's portfolio.
Then there's APG279, a combination therapy that pairs zumilokibart with another Apogee molecule called APG990, which targets OX40L (a protein involved in a different arm of the immune response). The idea is to block two inflammatory pathways at once. A Phase 1b trial of APG279 going head-to-head against Dupixent in atopic dermatitis is already underway, with results expected in the second half of 2026.
If that combination outperforms Dupixent, it could reshape the entire competitive landscape.
Apogee also has APG333, an early-stage immunology candidate that reported positive interim Phase 1 healthy volunteer data in November 2025. It's early, but it adds depth to a pipeline that AbbVie clearly sees as strategically valuable.
Wall Street's Verdict: Smart, But Patient
The market's reaction was cautiously optimistic. Apogee shares jumped sharply on the news. AbbVie ticked up modestly, which in M&A world translates to: "We don't hate this."
RBC Capital Markets analyst Brian Abrahams called the deal "logical" and said AbbVie was the "perfect buyer" to unlock zumilokibart's potential. That framing is important. Apogee is a clinical-stage biotech with no sales force, no manufacturing infrastructure, and no regulatory track record. AbbVie has all of those things, plus the world's most experienced immunology commercial team.
But there's a catch. AbbVie's own projections say this deal will hurt earnings per share by about $0.14 in 2026 and $0.46 in 2027. It won't turn accretive until 2032. That's a six-year wait. AbbVie is essentially telling shareholders: trust us, this is a long game.
To finance the deal, AbbVie is taking on debt, though the company says it plans to maintain its A-2/A- credit rating and get back to a 2x net leverage ratio within two to three years. No changes to dividends. No changes to capital allocation priorities. The message: this is a big bet, but a manageable one.
The Founding Story Is Wild
It's worth pausing to appreciate how fast Apogee moved. The company was spun out of Paragon Therapeutics and co-founded by Fairmount Funds and Venrock Healthcare Capital Partners in 2022. It raised $169 million privately, including a $149 million Series B led by Deep Track Capital and RTW Investments.
Then came the July 2023 IPO at $17 per share, raising about $315 million net. In a brutal year for biotech IPOs, Apogee managed to pull off one of the largest debuts.
From founding to a $10.9 billion buyout in roughly four years. The early investors who backed Apogee at the venture stage are looking at a return that most VCs only dream about. Fairmount and Venrock, along with key shareholders, have already signed voting agreements supporting the deal.
What This Means for the Atopic Dermatitis Arms Race
Dupixent still controls the atopic dermatitis biologics market, and its moat is formidable. It spans six indications, has years of real-world safety data, and enjoys deep payer relationships. Competing with Dupixent isn't just about clinical data; it's about access, pricing, and physician comfort.
But the next wave is coming. Eli Lilly's lebrikizumab and LEO Pharma's tralokinumab are already in market as anti-IL-13 alternatives. Programs targeting OX40/OX40L and other immune mechanisms are advancing. The question facing every competitor is the same: can you offer something meaningfully different from the drug that 55-60% of the market already uses?
Zumilokibart's answer is convenience. Quarterly or biannual dosing in a disease that requires lifelong treatment is a compelling pitch to patients and doctors alike. Paired with AbbVie's commercial firepower, it could carve out serious market share.
The Bottom Line
AbbVie's $10.9 billion Apogee acquisition is the company's clearest signal yet that it's planning for a world well beyond Skyrizi and Rinvoq. The deal closes in Q3 2026, pending shareholder and regulatory approvals. Both boards have unanimously signed off.
Six years of EPS dilution is a long time to wait. But if zumilokibart's Phase 2 results hold up in Phase 3, and if the asthma and combination programs deliver, AbbVie could own the next generation of immunology blockbusters.
It's a bet on science that doesn't have a final answer yet. Then again, the best deals in biotech rarely do.
Clinical & Regulatory5 min read
CRISPR Just Got Cleared for Toddlers. Yes, Toddlers.
The FDA just approved a CRISPR gene therapy for kids as young as two, a world first. Casgevy's expansion into toddlers could prevent the silent organ damage that sickle cell disease inflicts from infancy, but delivering a treatment this complex to tiny patients is a whole different challenge.
